CN115778965B - New application of ligustrum lucidum glycoside G13 in preparing anti-myocardial fibrosis medicine - Google Patents
New application of ligustrum lucidum glycoside G13 in preparing anti-myocardial fibrosis medicine Download PDFInfo
- Publication number
- CN115778965B CN115778965B CN202211301805.0A CN202211301805A CN115778965B CN 115778965 B CN115778965 B CN 115778965B CN 202211301805 A CN202211301805 A CN 202211301805A CN 115778965 B CN115778965 B CN 115778965B
- Authority
- CN
- China
- Prior art keywords
- myocardial fibrosis
- myocardial
- glycoside
- ligustroside
- ligustrum lucidum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028594 Myocardial fibrosis Diseases 0.000 title claims abstract description 111
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 229930182470 glycoside Natural products 0.000 title claims description 64
- 150000002338 glycosides Chemical class 0.000 title claims description 64
- 241000830535 Ligustrum lucidum Species 0.000 title claims description 63
- 230000002107 myocardial effect Effects 0.000 claims abstract description 27
- 230000006907 apoptotic process Effects 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 230000036542 oxidative stress Effects 0.000 claims abstract description 21
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 20
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 20
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 20
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 16
- 230000006378 damage Effects 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 208000014674 injury Diseases 0.000 claims abstract description 16
- 208000031229 Cardiomyopathies Diseases 0.000 claims abstract description 12
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 9
- 206010019280 Heart failures Diseases 0.000 claims abstract description 7
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 7
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 7
- 208000024891 symptom Diseases 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- GMQXOLRKJQWPNB-UHFFFAOYSA-N (8E)-ligstroside Natural products CC=C1C(CC(=O)OCCC=2C=CC(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O GMQXOLRKJQWPNB-UHFFFAOYSA-N 0.000 claims description 38
- GMQXOLRKJQWPNB-MVVLSVRYSA-N ligstroside Chemical compound O([C@@H]\1OC=C([C@H](C/1=C\C)CC(=O)OCCC=1C=CC(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMQXOLRKJQWPNB-MVVLSVRYSA-N 0.000 claims description 38
- 235000013399 edible fruits Nutrition 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 244000242564 Osmanthus fragrans Species 0.000 claims description 12
- 235000019083 Osmanthus fragrans Nutrition 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 241000735234 Ligustrum Species 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 10
- 239000003480 eluent Substances 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 10
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 238000011068 loading method Methods 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 238000005238 degreasing Methods 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 239000012452 mother liquor Substances 0.000 claims description 5
- 239000010413 mother solution Substances 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 238000002137 ultrasound extraction Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000007791 liquid phase Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- ZOLPMMWNCLHKPX-UHFFFAOYSA-N ligustrin Natural products CC1=CCC2C1C3OC(=C)C(=O)C3C(O)CC2=C ZOLPMMWNCLHKPX-UHFFFAOYSA-N 0.000 abstract description 23
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 abstract description 23
- 230000019491 signal transduction Effects 0.000 abstract description 16
- 238000011160 research Methods 0.000 abstract description 3
- 238000011269 treatment regimen Methods 0.000 abstract description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 32
- 229940039009 isoproterenol Drugs 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 14
- 241000333181 Osmanthus Species 0.000 description 12
- 235000019082 Osmanthus Nutrition 0.000 description 12
- 102000012422 Collagen Type I Human genes 0.000 description 9
- 108010022452 Collagen Type I Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 235000008504 concentrate Nutrition 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 239000000945 filler Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 6
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 210000005003 heart tissue Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000011532 immunohistochemical staining Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 4
- 101001109714 Rhizobium meliloti (strain 1021) NAD(P)H dehydrogenase (quinone) 1 Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012982 microporous membrane Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000003952 Caspase 3 Human genes 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 3
- 102000001187 Collagen Type III Human genes 0.000 description 3
- 108010069502 Collagen Type III Proteins 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 2
- 101700026522 SMAD7 Proteins 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 102000055102 bcl-2-Associated X Human genes 0.000 description 2
- 108700000707 bcl-2-Associated X Proteins 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- -1 electuaries Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000013424 sirius red staining Methods 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- 241000201320 Ligustrum japonicum Species 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- DHCJUOOZDMXKGF-UHFFFAOYSA-L [Na+].[Na+].OC(=O)CC(O)(CC([O-])=O)C(O)=O.OC(=O)CC(O)(CC([O-])=O)C(O)=O Chemical compound [Na+].[Na+].OC(=O)CC(O)(CC([O-])=O)C(O)=O.OC(=O)CC(O)(CC([O-])=O)C(O)=O DHCJUOOZDMXKGF-UHFFFAOYSA-L 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000007726 cellular glucose metabolism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a novel application of ligustrin G13 in preparing medicines for resisting myocardial fibrosis, which belongs to the technical field of medicines, namely the novel application of ligustrin G13 in preparing medicines for treating, preventing, relieving or alleviating myocardial fibrosis related diseases, wherein the myocardial fibrosis related diseases refer to diseases caused by myocardial fibrosis or diseases which can develop into myocardial fibrosis or diseases with clinical symptoms of myocardial fibrosis, including but not limited to coronary heart disease, myocardial ischemia, myocardial infarction and heart failure. The ligustrin G13 can reduce myocardial apoptosis by relieving oxidative stress injury, inhibit TGF-beta 1/Smads signal pathway and relieve ISO-induced myocardial fibrosis, play a role in resisting myocardial fibrosis, provide a new treatment strategy for preparing anti-myocardial fibrosis medicine research, and have good prospect for developing and applying the anti-myocardial fibrosis medicine.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a novel application of ligustroside G13 in preparation of an anti-myocardial fibrosis medicine.
Background
Cardiovascular disease is a well-recognized disease with a high incidence and mortality rate worldwide. Myocardial fibrosis is a core pathological change of various cardiovascular diseases (coronary heart disease, myocardial ischemia and myocardial infarction) which progress to a certain stage, and is also an important cause of heart failure, and is an important point and difficulty of the current clinical treatment. The medicines for treating myocardial fibers are few in clinic, and the existing western medicines have the problem of insufficient safety in clinical application and are accompanied with certain adverse reactions and side effects. Therefore, the anti-myocardial fibrosis medicine which is purely natural in source, good in treatment effect and low in toxic and side effects has important clinical requirements.
The molecular formula of the ligustrum lucidum glycoside G13 is C48H64O27, and the ligustrum lucidum glycoside G is a main active ingredient in Chinese medicinal ligustrum lucidum fruits and osmanthus fragrans fruits. Previous studies have found that ligustrin G13 can increase blood glucose consumption, affect cellular glucose metabolism, and improve insulin resistance in HepG2 insulin resistance cell model. Meanwhile, in osteoblast UMR-106, ligustrum japonicum G13 exerts an anti-osteoporosis effect by enhancing alkaline phosphatase (ALP) activity in serum. In addition, ligustrin G13 was found to have anti-platelet aggregation, antioxidant and anti-inflammatory activity. However, no report is available on the prevention and treatment effect of ligustrin G13 on myocardial fibrosis at present.
Isoproterenol (ISO) is a beta receptor agonist used in bronchial asthma and atrioventricular block, and can induce myocardial fibrosis. ISO-induced myocardial fibrosis is a classical animal model of myocardial fibrosis research that can mimic the pathological process of clinical myocardial fibrosis for evaluation of the effects of drugs on oxidative stress, inflammation, and apoptosis of the heart. Experimental data in the technical scheme disclosed by the invention is provided by constructing an ISO-induced mouse myocardial fibrosis model.
Disclosure of Invention
The invention aims at providing a new application of ligustrin G13 in preparing medicines for resisting myocardial fibrosis. Namely, the novel application of the ligustrum lucidum glycoside G13 in preparing medicaments for treating, preventing, relieving or alleviating myocardial fibrosis related diseases reduces myocardial cell apoptosis by alleviating oxidative stress injury, inhibits TGF-beta 1/Smads signal channels to alleviate ISO-induced myocardial fibrosis, plays a role in resisting myocardial fibrosis, and provides a novel treatment strategy for preparing anti-myocardial fibrosis medicament researches.
In order to achieve the above purpose, the technical scheme adopted is as follows:
the novel application of the ligustrum lucidum glycoside G13 in preparing medicaments for resisting myocardial fibrosis, namely in preparing medicaments for treating, preventing, relieving or alleviating myocardial fibrosis related diseases.
Wherein the myocardial fibrosis related diseases refer to diseases caused by myocardial fibrosis or diseases which can develop into myocardial fibrosis or diseases with clinical symptoms of myocardial fibrosis, including but not limited to coronary heart disease, myocardial ischemia, myocardial infarction and heart failure.
Wherein, the ligustrum lucidum glycoside G13 plays a role in resisting myocardial fibrosis by reducing oxidative stress injury, reducing myocardial apoptosis and inhibiting TGF-beta 1/Smads signaling pathway to reduce ISO-induced myocardial fibrosis.
Wherein the ligustrin G13 reduces myocardial apoptosis by relieving oxidative stress injury, and inhibits TGF-beta 1/Smads signaling pathway to relieve ISO-induced myocardial fibrosis, and the effective concentration for resisting myocardial fibrosis is 20-80mg/kg/d.
Wherein the ligustrum lucidum glycoside G13 has a structural formula of (1):
wherein the ligustrin G13 is extracted from glossy privet fruits and osmanthus fruits, but is not limited to glossy privet fruits and osmanthus fruits, wherein the extraction process from the osmanthus fruits comprises the following steps: degreasing dried osmanthus fragrans fruits with petroleum ether, performing ultrasonic extraction for 1h by adopting 55% ethanol according to a feed-liquid ratio of 1:10, recovering the extracting solution by using a rotary evaporator at 40 ℃, freeze-drying to obtain an osmanthus fragrans fruit extract, dissolving the extract with water, and preparing a mother solution with a concentration of 5 mg/mL; enriching the ligustrum lucidum glycoside G13 by using macroporous resin with the model of XAD-16, loading the sample at the flow rate of 1mL/min, and stopping loading the sample when detecting the concentration of the ligustrum lucidum glycoside G13 in the resin effluent to 5% of the concentration in the mother liquor by using HPLC; after the adsorption reaches equilibrium, eluting impurities with 30% ethanol, detecting by HPLC until the occurrence of ligustroside G13 in the eluent begins, eluting with 40% ethanol in a large amount, collecting 40% ethanol eluent, recovering by rotary evaporator at 40deg.C, and lyophilizing to obtain ligustroside G13 concentrate; dissolving the ligustrum glycoside G13 concentrate with methanol, filtering with 0.22 μm microporous membrane, purifying and preparing ligustrum glycoside G13 with 0.1% phosphoric acid water (A) -acetonitrile (B) as mobile phase, and performing gradient elution under conditions of 0-10min and 10-30% B with YMC-Pack ODS-A C chromatographic column (20×250mm,5 μm) at flow rate of 8mL/min and detection wavelength of 210 nm; 10-25min,30%; collecting the ligustroside G13 flowing out from the chromatographic column according to the retention time of the ligustroside G13 by adopting a manual collection mode, recovering the ligustroside G13 by using a rotary evaporator at 40 ℃, and freeze-drying to obtain the ligustroside G13.
Wherein, when the ligustrum lucidum glycoside G13 is used as a medicament for treating, preventing, relieving or alleviating myocardial fibrosis, the ligustrum lucidum glycoside G13 can be directly used or used in the form of a pharmaceutical composition, and the pharmaceutical composition contains 0.1-99% of the ligustrum lucidum glycoside G13 and the balance of a medicinal carrier or excipient.
A medicament for treating, preventing, alleviating or alleviating myocardial fibrosis, comprising ligustroside G13 and a pharmaceutically acceptable carrier.
Wherein the pharmaceutically acceptable carrier is one or more of solid, semi-solid and liquid diluents, fillers and pharmaceutical product adjuvants, including fillers, diluents, emulsifiers, disintegrants, binders and drug-carrying carriers without toxic or side effects.
Wherein the dosage form of the medicine is as follows: tablets, injections, suspensions, emulsions, solutions, syrups, tablets, capsules, granules, electuaries, sprays and aerosols.
Compared with the prior art, the ligustrum lucidum glycoside G13 has never been reported to have anti-myocardial fibrosis activity and is used for treating myocardial fibrosis related diseases. The invention discloses application of ligustrin G13 in preparing medicines for treating, preventing, relieving or alleviating myocardial fibrosis, and experimental data show that the exact improvement and treatment effect of ligustrin G13 on myocardial fibrosis can obviously improve ISO-induced myocardial fibrosis. Animal experiments show that the natural iridoid glycoside component ligustrin G13 can reduce myocardial apoptosis by relieving oxidative stress injury, inhibit TGF-beta 1/Smads signal pathway to relieve ISO-induced myocardial fibrosis, and play an anti-myocardial fibrosis role.
Drawings
FIG. 1 shows the chemical structure of ligustrum lucidum glycoside G13;
FIG. 2 is the effect of ligustrin G13 on cardiac morphology, cardiac index and cardiac function in mice;
FIG. 3 is the effect of ligustrum lucidum glycoside G13 on oxidative stress markers;
FIG. 4 is a graph showing that ligustrin G13 induces the expression of type I collagen, type III collagen and alpha-SMA in myocardial tissue of mice;
FIG. 5 is the effect of ligustrin G13 on heart histopathology and hepatotoxicity;
FIG. 6 is the effect of ligustrin G13 on apoptosis in mice with myocardial fibrosis;
FIG. 7 is the effect of ligustrum lucidum glycoside G13 on TGF-beta 1/Smads signaling pathway.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to be limiting.
Example 1
The novel application of the ligustrum lucidum glycoside G13 in preparing medicaments for resisting myocardial fibrosis, namely in preparing medicaments for treating, preventing, relieving or alleviating myocardial fibrosis related diseases.
Wherein the myocardial fibrosis related diseases refer to diseases caused by myocardial fibrosis or diseases which can develop into myocardial fibrosis or diseases with clinical symptoms of myocardial fibrosis, including but not limited to coronary heart disease, myocardial ischemia, myocardial infarction and heart failure.
Wherein, the ligustrum lucidum glycoside G13 plays a role in resisting myocardial fibrosis by reducing oxidative stress injury, reducing myocardial apoptosis and inhibiting TGF-beta 1/Smads signaling pathway to reduce ISO-induced myocardial fibrosis.
Wherein the ligustrin G13 reduces myocardial apoptosis by alleviating oxidative stress injury, and inhibits TGF-beta 1/Smads signaling pathway to alleviate ISO-induced myocardial fibrosis, and the effective concentration for resisting myocardial fibrosis is 20mg/kg/d.
Wherein the ligustrum lucidum glycoside G13 has a structural formula of (1):
wherein the ligustrin G13 is extracted from glossy privet fruits and osmanthus fruits, but is not limited to glossy privet fruits and osmanthus fruits, wherein the extraction process from the osmanthus fruits comprises the following steps: degreasing dried osmanthus fragrans fruits with petroleum ether, performing ultrasonic extraction for 1h by adopting 55% ethanol according to a feed-liquid ratio of 1:10, recovering the extracting solution by using a rotary evaporator at 40 ℃, freeze-drying to obtain an osmanthus fragrans fruit extract, dissolving the extract with water, and preparing a mother solution with a concentration of 5 mg/mL; enriching the ligustrum lucidum glycoside G13 by using macroporous resin with the model of XAD-16, loading the sample at the flow rate of 1mL/min, and stopping loading the sample when detecting the concentration of the ligustrum lucidum glycoside G13 in the resin effluent to 5% of the concentration in the mother liquor by using HPLC; after the adsorption reaches equilibrium, eluting impurities with 30% ethanol, detecting by HPLC until the occurrence of ligustroside G13 in the eluent begins, eluting with 40% ethanol in a large amount, collecting 40% ethanol eluent, recovering by rotary evaporator at 40deg.C, and lyophilizing to obtain ligustroside G13 concentrate; dissolving the ligustrum glycoside G13 concentrate with methanol, filtering with 0.22 μm microporous membrane, purifying and preparing ligustrum glycoside G13 with 0.1% phosphoric acid water (A) -acetonitrile (B) as mobile phase, and performing gradient elution under conditions of 0-10min and 10-30% B with YMC-Pack ODS-A C chromatographic column (20×250mm,5 μm) at flow rate of 8mL/min and detection wavelength of 210 nm; 10-25min,30%; collecting the ligustroside G13 flowing out from the chromatographic column according to the retention time of the ligustroside G13 by adopting a manual collection mode, recovering the ligustroside G13 by using a rotary evaporator at 40 ℃, and freeze-drying to obtain the ligustroside G13.
Wherein, when the ligustrum lucidum glycoside G13 is used as a medicament for treating, preventing, relieving or alleviating myocardial fibrosis, the ligustrum lucidum glycoside G13 can be directly used or used in the form of a pharmaceutical composition, and the pharmaceutical composition contains 0.1-99% of the ligustrum lucidum glycoside G13 and the balance of a medicinal carrier or excipient.
A medicament for treating, preventing, alleviating or alleviating myocardial fibrosis, comprising ligustroside G13 and a pharmaceutically acceptable carrier.
Wherein the pharmaceutically acceptable carrier is one or more of solid, semi-solid and liquid diluents, fillers and pharmaceutical product adjuvants, including fillers, diluents, emulsifiers, disintegrants, binders and drug-carrying carriers without toxic or side effects.
Wherein the dosage form of the medicine is as follows: a tablet.
Example 2
The novel application of the ligustrum lucidum glycoside G13 in preparing medicaments for resisting myocardial fibrosis, namely in preparing medicaments for treating, preventing, relieving or alleviating myocardial fibrosis related diseases.
Wherein the myocardial fibrosis related diseases refer to diseases caused by myocardial fibrosis or diseases which can develop into myocardial fibrosis or diseases with clinical symptoms of myocardial fibrosis, including but not limited to coronary heart disease, myocardial ischemia, myocardial infarction and heart failure.
Wherein, the ligustrum lucidum glycoside G13 plays a role in resisting myocardial fibrosis by reducing oxidative stress injury, reducing myocardial apoptosis and inhibiting TGF-beta 1/Smads signaling pathway to reduce ISO-induced myocardial fibrosis.
Wherein the ligustrin G13 reduces myocardial apoptosis by alleviating oxidative stress injury, and inhibits TGF-beta 1/Smads signaling pathway to alleviate ISO-induced myocardial fibrosis, and the effective concentration for resisting myocardial fibrosis is 80mg/kg/d.
Wherein the ligustrum lucidum glycoside G13 has a structural formula of (1):
wherein the ligustrin G13 is extracted from glossy privet fruits and osmanthus fruits, but is not limited to glossy privet fruits and osmanthus fruits, wherein the extraction process from the osmanthus fruits comprises the following steps: degreasing dried osmanthus fragrans fruits with petroleum ether, performing ultrasonic extraction for 1h by adopting 55% ethanol according to a feed-liquid ratio of 1:10, recovering the extracting solution by using a rotary evaporator at 40 ℃, freeze-drying to obtain an osmanthus fragrans fruit extract, dissolving the extract with water, and preparing a mother solution with a concentration of 5 mg/mL; enriching the ligustrum lucidum glycoside G13 by using macroporous resin with the model of XAD-16, loading the sample at the flow rate of 1mL/min, and stopping loading the sample when detecting the concentration of the ligustrum lucidum glycoside G13 in the resin effluent to 5% of the concentration in the mother liquor by using HPLC; after the adsorption reaches equilibrium, eluting impurities with 30% ethanol, detecting by HPLC until the occurrence of ligustroside G13 in the eluent begins, eluting with 40% ethanol in a large amount, collecting 40% ethanol eluent, recovering by rotary evaporator at 40deg.C, and lyophilizing to obtain ligustroside G13 concentrate; dissolving the ligustrum glycoside G13 concentrate with methanol, filtering with 0.22 μm microporous membrane, purifying and preparing ligustrum glycoside G13 with 0.1% phosphoric acid water (A) -acetonitrile (B) as mobile phase, and performing gradient elution under conditions of 0-10min and 10-30% B with YMC-Pack ODS-A C chromatographic column (20×250mm,5 μm) at flow rate of 8mL/min and detection wavelength of 210 nm; 10-25min,30%; collecting the ligustroside G13 flowing out from the chromatographic column according to the retention time of the ligustroside G13 by adopting a manual collection mode, recovering the ligustroside G13 by using a rotary evaporator at 40 ℃, and freeze-drying to obtain the ligustroside G13.
Wherein, when the ligustrum lucidum glycoside G13 is used as a medicament for treating, preventing, relieving or alleviating myocardial fibrosis, the ligustrum lucidum glycoside G13 can be directly used or used in the form of a pharmaceutical composition, and the pharmaceutical composition contains 0.1-99% of the ligustrum lucidum glycoside G13 and the balance of a medicinal carrier or excipient.
A medicament for treating, preventing, alleviating or alleviating myocardial fibrosis, comprising ligustroside G13 and a pharmaceutically acceptable carrier.
Wherein the pharmaceutically acceptable carrier is one or more of solid, semi-solid and liquid diluents, fillers and pharmaceutical product adjuvants, including fillers, diluents, emulsifiers, disintegrants, binders and drug-carrying carriers without toxic or side effects.
Wherein the dosage form of the medicine is as follows: tablets, injections, suspensions, emulsions, solutions, syrups, capsules, granules, sprays and aerosols.
Example 3
The novel application of the ligustrum lucidum glycoside G13 in preparing medicaments for resisting myocardial fibrosis, namely in preparing medicaments for treating, preventing, relieving or alleviating myocardial fibrosis related diseases.
Wherein the myocardial fibrosis related diseases refer to diseases caused by myocardial fibrosis or diseases which can develop into myocardial fibrosis or diseases with clinical symptoms of myocardial fibrosis, including but not limited to coronary heart disease, myocardial ischemia, myocardial infarction and heart failure.
Wherein, the ligustrum lucidum glycoside G13 plays a role in resisting myocardial fibrosis by reducing oxidative stress injury, reducing myocardial apoptosis and inhibiting TGF-beta 1/Smads signaling pathway to reduce ISO-induced myocardial fibrosis.
Wherein the effective concentration of the ligustrum lucidum glycoside G13 for exerting the anti-myocardial fibrosis effect is 40mg/kg/d by reducing oxidative stress injury, reducing myocardial apoptosis and inhibiting TGF-beta 1/Smads signal pathway to reduce ISO-induced myocardial fibrosis.
Wherein the ligustrum lucidum glycoside G13 has a structural formula of (1):
wherein the ligustrin G13 is extracted from glossy privet fruits and osmanthus fruits, but is not limited to glossy privet fruits and osmanthus fruits, wherein the extraction process from the osmanthus fruits comprises the following steps: degreasing dried osmanthus fragrans fruits with petroleum ether, performing ultrasonic extraction for 1h by adopting 55% ethanol according to a feed-liquid ratio of 1:10, recovering the extracting solution by using a rotary evaporator at 40 ℃, freeze-drying to obtain an osmanthus fragrans fruit extract, dissolving the extract with water, and preparing a mother solution with a concentration of 5 mg/mL; enriching the ligustrum lucidum glycoside G13 by using macroporous resin with the model of XAD-16, loading the sample at the flow rate of 1mL/min, and stopping loading the sample when detecting the concentration of the ligustrum lucidum glycoside G13 in the resin effluent to 5% of the concentration in the mother liquor by using HPLC; after the adsorption reaches equilibrium, eluting impurities with 30% ethanol, detecting by HPLC until the occurrence of ligustroside G13 in the eluent begins, eluting with 40% ethanol in a large amount, collecting 40% ethanol eluent, recovering by rotary evaporator at 40deg.C, and lyophilizing to obtain ligustroside G13 concentrate; dissolving the ligustrum glycoside G13 concentrate with methanol, filtering with 0.22 μm microporous membrane, purifying and preparing ligustrum glycoside G13 with 0.1% phosphoric acid water (A) -acetonitrile (B) as mobile phase, and performing gradient elution under conditions of 0-10min and 10-30% B with YMC-Pack ODS-A C chromatographic column (20×250mm,5 μm) at flow rate of 8mL/min and detection wavelength of 210 nm; 10-25min,30%; collecting the ligustroside G13 flowing out from the chromatographic column according to the retention time of the ligustroside G13 by adopting a manual collection mode, recovering the ligustroside G13 by using a rotary evaporator at 40 ℃, and freeze-drying to obtain the ligustroside G13.
Wherein, when the ligustrum lucidum glycoside G13 is used as a medicament for treating, preventing, relieving or alleviating myocardial fibrosis, the ligustrum lucidum glycoside G13 can be directly used or used in the form of a pharmaceutical composition, and the pharmaceutical composition contains 0.1-99% of the ligustrum lucidum glycoside G13 and the balance of a medicinal carrier or excipient.
A medicament for treating, preventing, alleviating or alleviating myocardial fibrosis, comprising ligustroside G13 and a pharmaceutically acceptable carrier.
Wherein the pharmaceutically acceptable carrier is one or more of solid, semi-solid and liquid diluents, fillers and pharmaceutical product adjuvants, including fillers, diluents, emulsifiers, disintegrants, binders and drug-carrying carriers without toxic or side effects.
Wherein the dosage form of the medicine is as follows: tablets, injections, suspensions, emulsions, solutions, syrups, tablets, capsules, granules, electuaries, sprays and aerosols.
The foregoing description is only a preferred embodiment of the present invention, and is not intended to limit the invention in any way, and any simple modification, material transformation, equivalent changes and modification made to the above embodiment according to the technical matter of the present invention still fall within the scope of the technical scheme of the present invention.
In order to further verify the novel application of the ligustrin G13 (hereinafter referred to as G13) in preparing medicaments for treating, preventing, relieving or alleviating myocardial fibrosis related diseases, namely, reducing myocardial apoptosis by alleviating oxidative stress injury, inhibiting TGF-beta 1/Smads signal channels to alleviate ISO-induced myocardial fibrosis, playing an anti-myocardial fibrosis role, animal experiments are designed as follows.
1. In vivo experiments
Mice were randomly divided into 6 groups: the control group, the model group, the G13 low dose group (20 mg/kg), the G13 medium dose group (40 mg/kg), the G13 high dose group (80 mg/kg) and the G13 drug group (80 mg/kg), the control group is given by intragastric administration and subcutaneous injection of 0.9% physiological saline (10 mg/kg/d), the model group is given by intragastric administration and subcutaneous injection of 0.9% physiological saline ISO (10 mg/kg/d), the G13 low dose group, the G13 medium dose group and the G13 high dose group are respectively given by intragastric administration and the G13 (20, 40, 80 mg/kg/d) are given by subcutaneous injection and the G13 drug group is given by intragastric administration only (80 mg/kg/d). Each set of experiments lasted 21 days. After 21 days, each group of mice was weighed, electrocardiographic examination was performed, blood was collected from the eyes, and hearts and livers were collected after sacrifice. The heart and liver were freed from blood traces in physiological saline, dried with filter paper, weighed, and heart index calculated. The results of the CK (creatine kinase) and LDH (lactate dehydrogenase) assays on mouse serum using the kit procedure are shown in figure 2 for the effects of G13 on mouse heart morphology, heart index and heart function. (wherein A is the morphology of the heart of each group of mice; B is the heart index of each group of mice; C and D are changes in serum CK and LDH levels of mice; E is the effect of G13 on ISO-induced electrocardiography of mice); the effect of G13 on oxidative stress markers is shown in FIG. 3. ( Wherein a-D is the change in oxidative stress markers in mouse heart tissue (n=6). E is immunohistochemical staining to detect expression of Nrf2 (scale bar: 50 μm). F is Western blotting to detect Nrf2, HO-1 and NQO-1 protein expression, and GAPDH is used as a control. G-I is the gray value analysis of Nrf2, HO-1, NQO-1 (n=3). )
As can be seen from fig. 2, the heart color of the G13 mice was close to normal, and the volume was also significantly reduced. The CWI of the ISO group was significantly higher than the control group, while the CWI of the G13 group was significantly reduced, indicating that G13 could alleviate ISO-induced myocardial hypertrophy. Meanwhile, the myocardial enzyme level of the ISO group is obviously increased, and the myocardial enzyme activity is obviously reduced after G13 is added, so that the G13 has a protective effect on ISO-induced myocardial injury. The contrast group has normal electrocardiogram, while the ISO group has low T wave, reduced QRS wave amplitude and increased S-T segment, which indicates the occurrence of myocardial ischemia symptoms. After administration of G13, T-wave was elevated and S-T segment was significantly restored, indicating that G13 could ameliorate ISO-induced myocardial ischemia.
As can be seen from fig. 3, the expression of key proteins associated with oxidative stress was detected using immunohistochemical staining and western blotting, and Nrf2 was expressed significantly lower in the ISO group than in the normal group, and G13 recovered its expression in a dose-dependent manner. On the other hand, the expression of Nrf2, HO-1 and NQO-1 is down-regulated under the stimulation of ISO, and after G13 treatment, the expression levels of Nrf2, HO-1 and NQO-1 are up-regulated, so that the G13 can be proved to be capable of relieving oxidative stress injury caused by myocardial fibrosis.
2. Immunohistochemical staining and western blotting
The extent of fibrosis was assessed by measuring the expression of type I collagen and alpha-SMA in myocardial tissue using immunohistochemical staining and western blotting. The specific operation is as follows: fixed heart samples were embedded in paraffin and cut into 4 μm sections. Heart sections were deparaffinized and hydrated and then immersed in sodium citrate-sodium citrate buffer for antigen retrieval, then sections were incubated in 3% hydrogen peroxide to quench endogenous peroxidase activity and blocked with goat serum to prevent non-specific antibody binding. Subsequently, the tissue samples were incubated with primary antibody overnight at 4 ℃, and the secondary antibody was left at room temperature for 15 minutes. The slides were then washed with Tris Buffered Saline (TBS). Horseradish peroxidase (HRP) -labeled secondary antibody was added, incubated at 37 ℃ for 15-20 min, then developed with Diaminobenzidine (DAB) and counterstained with hematoxylin, and finally the target protein was quantitatively analyzed. The results of G13 induction of the expression of type I collagen, type III collagen and α -SMA in mouse heart tissue are shown in FIG. 4 (wherein A is immunohistochemical staining analysis (scale: 50 μm) of collagen I and α -SMA in each group of mouse heart tissue; B-C is quantitative analysis of positive expression of collagen I and α -SMA; D is gray value analysis of Western blotting to detect protein expression of collagen I, collagen III and α -SMA; E is type I collagen, type III collagen and α -SMA (n=3); the effect of G13 on heart histopathology and hepatotoxicity is shown in FIG. 5 (A is HE and sirius red staining for detection of myocardial tissue (scale: 50 μm). B is a quantitative analysis of collagen fibers in heart tissue. C is H & E and Masson staining for G13 hepatotoxicity).
As can be seen from fig. 4, the expression of the collagen I and α -SMA in the ISO group was strongly positive, and the expression of both was reduced after the G13 treatment, indicating that the G13 treatment inhibited the expression of the collagen I and α -SMA, indicating that the myocardial fibrosis model was successfully established.
As can be seen from fig. 5, after H & E staining, the ISO group of mice showed significant fiber bundles, myocardial structural disorders and inflammatory cell infiltration. After G13 treatment, myocardial structural disorders and fibrosis levels improved in a dose-dependent manner. Sirius red staining results showed that model group collagen fibers were significantly higher than control group, while G13 dose-dependent improved collagen fiber deposition. In addition, H & E and Masson staining of mouse liver tissue showed neat alignment of hepatocytes, no inflammatory cell infiltration, no collagen fiber deposition, demonstrating no toxic effects of G13.
3. Assessment of extent of myocardial apoptosis following myocardial fibrosis using TUNEL staining
TUNEL staining was used to assess the extent of cardiomyocyte apoptosis following myocardial fibrosis. The specific operation is as follows: after the mice were sacrificed, heart tissue was removed, 4% paraformaldehyde was fixed for 24 hours, and paraffin embedded. Dewaxing, rehydration, adding proteinase K working solution, incubating at 37℃for 22 min, washing 3 times with PBS (pH 7.4) in a Rocker apparatus for 5min each. After the sections were dried, a permeabilization working solution was added for 20 minutes at 37℃and then washed with PBS. After the sections were slightly dried, buffer was added to the tissue in the sheet and the buffer incubated at room temperature for 10 minutes. Appropriate amounts of TDT enzyme, dUTP and buffer were mixed in fixed proportions, covered tissue, incubated in a 37 ℃ wet box for 2 hours, and washed with PBS. DAPI dye solution was added and incubated for 10 minutes at room temperature, washed with PBS, the liquid removed, and then coverslips with fade-resistant mounting agent. Microscopy and image collection were performed by fluorescence microscopy. The effect of G13 on apoptosis in mice with myocardial fibrosis is shown in FIG. 6 (wherein A is TUNEL fluorescent staining (scale: 20 μm) of heart tissue sections, apoptotic cells (green) and nuclei (blue). B is a gray-scale analysis of Western blotting for detection of Bcl-2, bax and Caspase-3 protein expression, GAPDH as control. C-F is Bcl-2, bax and Caspase-3 (n=3)).
Fig. 6 shows that the number of myocardial apoptosis increases significantly under ISO stimulation, while the number of myocardial apoptosis decreases in a dose-dependent manner under G13, indicating that myocardial fibrosis is involved in apoptosis. Meanwhile, bcl-2 is found to be significantly down-regulated under ISO stimulation, bax and Caspase-3 are significantly up-regulated as pro-apoptotic molecules, and after G13 is added for treatment, the ratio of Bcl-2/Bax is increased, so that G13 can be proved to reduce myocardial fibrosis and inhibit apoptosis.
4. Study of the Effect of glossy privet glycoside G13 on TGF-beta 1/Smads Signal pathway by Wsterin blot technique
The influence of the ligustrum lucidum glycoside G13 on the classical TGF-beta 1/Smads signal path of the tissue fibrosis is studied by adopting Wsterin blot and other technologies. The specific operation is as follows: the myocardial tissue of the mice was ground with a tissue grinder, the homogenate was placed in a refrigerator for 30min, centrifuged at-12000 g for 10min at-4℃and the supernatant was collected, and the protein content of the samples was determined by BCA method. The protein samples were boiled for 5 minutes and then separated by SDS polyacrylamide gel electrophoresis. The separated proteins were transferred to nitrocellulose membranes. 5% skim milk was soaked for 1.5 hours at room temperature. Incubate with primary antibody overnight at 4 ℃. Membranes were washed three times with TBS/0.1% Tween 20. Anti-mouse (1:2000) and anti-rabbit antibodies (1:1000) contain horseradish peroxidase. Finally, the protein was detected by enhanced chemiluminescence and immunoblots were quantified using image analysis software. The effect of G13 on the TGF-beta 1/Smads signaling pathway is shown in FIG. 7 (where A is the result of G13 affecting the TGF-beta 1/Smads signaling pathway. B is the P-Smad2 protein gray value analysis, smad2 is the control. C is the P-Smad3 protein gray value analysis, smad3 is the control. D-E is the gray value analysis of Smad7 and Smad 4).
As can be seen from fig. 7, the expression levels of TGF- β1, p-Smad2, p-Smad3 and Smad4 were significantly up-regulated in the ISO group, and the expression level of Smad7 was significantly down-regulated in the G13-administered group, compared to the control group, and the above expression was reversed, indicating that G13 has a cardioprotective effect and that myocardial fibrosis was inhibited by modulating TGF- β1/Smad signaling pathway.
Taken together, the analysis shows that ligustrin G13 can reduce myocardial apoptosis by reducing oxidative stress injury, and inhibit TGF-beta 1/Smads signaling pathway to reduce ISO-induced myocardial fibrosis. Wherein, the ligustrum lucidum glycoside G13 has the best anti-myocardial fibrosis effect under the administration condition of high dose (80 mg/kg/d), has no toxicity to liver and has very good prospect in developing and preparing anti-myocardial fibrosis medicines.
Claims (6)
1. The application of the ligustrum lucidum glycoside G13 as the only medicinal component in preparing the anti-myocardial fibrosis medicament is characterized in that: the structural formula of the compound is shown in the formula (1) in the specification, and the compound is applied to the preparation of medicines for treating, preventing, relieving or alleviating myocardial fibrosis related diseases:
2. the use of ligustrum lucidum glycoside G13 as the only active ingredient in the preparation of an anti-myocardial fibrosis drug according to claim 1, characterized in that: the myocardial fibrosis related diseases refer to diseases caused by myocardial fibrosis or diseases which can be developed into myocardial fibrosis or diseases with clinical symptoms of myocardial fibrosis, including but not limited to coronary heart disease, myocardial ischemia, myocardial infarction and heart failure.
3. The use of ligustrum lucidum glycoside G13 as the only active ingredient in the preparation of an anti-myocardial fibrosis drug according to claim 1, characterized in that: the ligustrum lucidum glycoside G13 has the effects of reducing myocardial cell apoptosis by relieving oxidative stress injury, inhibiting TGF-beta 1/Smads signal channels, relieving ISO-induced myocardial fibrosis and playing an anti-myocardial fibrosis role.
4. The use of ligustrum lucidum glycoside G13 as the only active ingredient in the preparation of an anti-myocardial fibrosis drug according to claim 1, characterized in that: the ligustrum lucidum glycoside G13 reduces myocardial cell apoptosis by reducing oxidative stress injury, inhibits TGF-beta 1/Smads signal channels to reduce ISO-induced myocardial fibrosis, and has an effective concentration of 20-80mg/kg/d for playing an anti-myocardial fibrosis role.
5. The use of ligustrum lucidum glycoside G13 as the only active ingredient in the preparation of an anti-myocardial fibrosis drug according to claim 1, characterized in that: the process for extracting osmanthus fragrans fruits comprises the following steps: degreasing dried osmanthus fragrans fruits with petroleum ether, performing ultrasonic extraction with 55% ethanol according to a feed-liquid ratio of 1:10 to obtain 1h, recovering the extracting solution at 40 ℃ with a rotary evaporator, freeze-drying to obtain an osmanthus fragrans fruit extract, dissolving the extract with water, and preparing a mother solution with a concentration of 5 mg/mL; enriching the ligustrum lucidum glycoside G13 by using macroporous resin with the model of XAD-16, loading the sample at the flow rate of 1mL/min, and stopping loading the sample when detecting the concentration of the ligustrum lucidum glycoside G13 in the resin effluent to 5% of the concentration in the mother liquor by using HPLC; after the adsorption reaches equilibrium, eluting impurities with 30% ethanol, detecting by HPLC until the occurrence of ligustroside G13 in the eluent begins, eluting with 40% ethanol in a large amount, collecting 40% ethanol eluent, recovering by rotary evaporator at 40deg.C, and lyophilizing to obtain ligustroside G13 concentrate; dissolving the ligustrum glycoside G13 concentrate with methanol, passing through a 0.22 μm microporous filter membrane, purifying and preparing ligustrum glycoside G13 by adopting a preparation liquid phase, taking 0.1% phosphoric acid water A-acetonitrile B as a mobile phase, selecting a YMC-Pack ODS-A C chromatographic column as a chromatographic column, and performing gradient elution under the conditions of 0-10min and 10-30% B, wherein the flow rate is 8mL/min, the detection wavelength is 210 nm; 10-25min,30%; collecting the ligustroside G13 flowing out from the chromatographic column according to the retention time of the ligustroside G13 by adopting a manual collection mode, recovering the ligustroside G13 by using a rotary evaporator at 40 ℃, and freeze-drying to obtain the ligustroside G13.
6. The use of ligustroside G13 as a sole active ingredient in the manufacture of a medicament for the treatment of myocardial fibrosis according to claim 1, wherein the ligustroside G13 is used directly or in the form of a pharmaceutical composition comprising 0.1 to 99% of ligustroside G13, the remainder being a pharmaceutically acceptable carrier or excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211301805.0A CN115778965B (en) | 2022-10-24 | 2022-10-24 | New application of ligustrum lucidum glycoside G13 in preparing anti-myocardial fibrosis medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211301805.0A CN115778965B (en) | 2022-10-24 | 2022-10-24 | New application of ligustrum lucidum glycoside G13 in preparing anti-myocardial fibrosis medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115778965A CN115778965A (en) | 2023-03-14 |
| CN115778965B true CN115778965B (en) | 2024-02-23 |
Family
ID=85433555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211301805.0A Active CN115778965B (en) | 2022-10-24 | 2022-10-24 | New application of ligustrum lucidum glycoside G13 in preparing anti-myocardial fibrosis medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115778965B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389440A (en) * | 2011-12-09 | 2012-03-28 | 四川浩源生物科技有限公司 | Application of iridoid in preparation of anti-osteoporosis medicines |
-
2022
- 2022-10-24 CN CN202211301805.0A patent/CN115778965B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389440A (en) * | 2011-12-09 | 2012-03-28 | 四川浩源生物科技有限公司 | Application of iridoid in preparation of anti-osteoporosis medicines |
Non-Patent Citations (3)
| Title |
|---|
| "女贞子中2种主要裂环环醚萜苷成分的分离鉴定及其抗氧化活性研究";李阳等;《中药材》;第第30卷卷(第第5期期);543-546 * |
| "红景天苷干预心血管系统药理研究进展";岳星星等;《中国中医药信息杂志》;第第24卷卷(第第3期期);130-133 * |
| 红景天苷对大鼠急性心肌梗死后心室重构相关作用及机制的研究;马杰等;中西医结合心脑血管病杂志;第15卷(第06期);671-676 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115778965A (en) | 2023-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hou et al. | Longzhibu disease and its therapeutic effects by traditional Tibetan medicine: Ershi-wei Chenxiang pills | |
| Kim et al. | Cinnamon subcritical water extract attenuates intestinal inflammation and enhances intestinal tight junction in a Caco-2 and RAW264. 7 co-culture model | |
| Yu et al. | A network pharmacology-based study on the mechanism of astragaloside IV alleviating renal fibrosis through the AKT1/GSK-3β pathway | |
| Zeng et al. | Effects of 1, 25-dihydroxyvitamin D3 on pathological changes in rats with diabetic cardiomyopathy | |
| Zhang et al. | Protective effects of flavonoids isolated from Agrocybe aegirita on dextran sodium sulfate‐induced colitis | |
| Shi et al. | Kaji-ichigoside F1 and rosamultin protect vascular endothelial cells against hypoxia-induced apoptosis via the PI3K/AKT or ERK1/2 signaling pathway | |
| CN110590873B (en) | Albizzia julibrissin new lignan compound | |
| Yao et al. | OEA alleviates apoptosis in diabetic rats with myocardial ischemia/reperfusion injury by regulating the PI3K/Akt signaling pathway through activation of TRPV1 | |
| CN108434139B (en) | Application of hypoxia-inducible factor prolyl hydroxylase activity inhibitor in preparation of medicine for preventing and treating acute kidney injury | |
| CN107349244B (en) | Extraction method of malonyl ginsenoside | |
| CN113842390A (en) | Lindera reflexa hemsl active ingredient composition with effect of preventing and treating gastric ulcer as well as preparation method and application thereof | |
| CN115778965B (en) | New application of ligustrum lucidum glycoside G13 in preparing anti-myocardial fibrosis medicine | |
| CN104161783B (en) | Application of the eupatorium lindleynun var. trifoliolatum sequiterpene position in resisting acute lung injury medicine is prepared | |
| JP6436618B2 (en) | Preparation of anti-tachyarrhythmia and preparation method thereof | |
| CN111356468A (en) | Composition for preventing or treating fibrotic disease comprising extract of Rhus toxicodendron | |
| Wang et al. | Celastrus orbiculatus extract inhibits the epithelial-mesenchymal transition process by transforming growth factor-β signaling pathway in gastric cancer | |
| Chen et al. | Lignin-carbohydrate complexes suppress SCA3 neurodegeneration via upregulating proteasomal activities | |
| CN107513092B (en) | Malonyl ginsenoside Rb1Preparation method and medical application thereof | |
| CN114432302A (en) | Application of small molecule SR9009 in resisting aging and relieving chronic inflammation caused by aging | |
| CN108066349A (en) | Applications of IV a of panax japonicus saponin in treatment ephritis or kidney fibrosis drug is prepared | |
| CN104922271B (en) | Application of the litchi rind polyphenol in the medicine or health products that reduce hepatic cholesterol is prepared | |
| CN103288889A (en) | Anthraquinone derivatives, their pharmaceutical compositions and application in medicine preparation | |
| KR20100059050A (en) | Composition for preventing or treating ceramide metabolism-related enzyme mediated disease comprising lignan derivatives as an active ingredient | |
| JP7353246B2 (en) | Nucleic acids and their use for the treatment or improvement of male metabolic syndrome | |
| CN114366752B (en) | Therapeutic effect of morinda-oligosaccharide 5-glycan monomer Hex5 on osteosarcoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |